MetabolicIn Clinical Trials

Cotadutide

Subcutaneous injection

Overview

Cotadutide is a dual agonist of the GLP-1 and glucagon receptors formulated as a peptide for subcutaneous injection. It is designed to harness GLP-1-mediated improvements in glucose homeostasis and satiety alongside glucagon receptor activation to enhance energy expenditure and reduce hepatic fat.

Mechanism of Action

Primary indications under investigation include obesity, type 2 diabetes, and metabolic dysfunction-associated steatohepatitis..

Research Summary & Key Findings

Phase 2 studies in patients with type 2 diabetes and non-alcoholic fatty liver disease showed reductions in body weight and liver fat. Data presented at liver and diabetes conferences in 2019 and 2020 supported continued investigation. Development status and phase 3 plans have not been widely updated in recent literature.

Clinical Status

In Clinical Trials

Cotadutide is currently undergoing clinical trials. It is not yet FDA-approved and is available only through clinical research settings or investigational protocols.

Administration Routes

Subcutaneous injection

Related Peptides in Metabolic

Find a Provider

Find a verified provider who offers Cotadutide therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Cotadutide.

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.